Phenotypic analysis of prostate-infiltrating lymphocytes reveals T H17 and Treg skewing

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3254-3261

  Sfanos, Karen Sandell ^a   Bruno, Tullia C ^a   Maris, Charles H ^a   Xu, Lauren ^a   Thoburn, Christopher J ^a   Demarzo, Angelo M ^a   Meeker, Alan K ^a   Isaacs, William B ^a   Drake, Charles G ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; PROTEIN LAG3; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ISOLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; TH17 CELL; ADULT; AGED; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; IMMUNOLOGY; MALE; MIDDLE AGED; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PHENOTYPE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION, GENETIC;

EID: 48849103649     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5164     Document Type: Article

References (39)

1. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratu-moralTcells, recurrence, and survival in epithelial ovarian cancer. N EnglJ Med 2003;348:203-13.
2. Gâlon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
3. Vesalainen S, Lipponen P. Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30A:1797-803.
4. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 2004;91:541 -3.
5. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 Tcell lineage with regulatoryTcell ties. Immunity 2006;24:677-88.
6. Bettelli E, Oukka M, KuchrooVK.T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50.
7. Steiner GE, Newman ME, Paikl D, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003:56:171 -82.
8. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11.
9. Liyanage UK, Moore TT, Joo H-G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
10. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005:65:2457-64.
11. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405.
12. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
13. Kono K, Kawaida H, Takahashi A, et al.
14. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006;55:1064-71.
15. Hori S, Nomura T, Sakaguchi S. Control of regulatory Tcell development by the transcription factor Foxp3. Science 2003;299:1057-61.
16. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N EnglJ Med 2003;349:366-81.
17. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005:7:211 -7.
18. Barrack ER.TGFß in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997;31:61 -70.
19. ChungTD,Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199 - 207.
20. Bettelli E, CarrierY, GaoW, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
21. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B.TGF[ß] in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producingTcells. Immunity 2006;24:179-89.
22. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-[ß] induces development of theTH17 lineage. Nature 2006;441:231 -4.
23. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-[ß] and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology [advanced online publication]. Nat Immunol 2007;8:1390-7.
24. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1 [ß] and 6 but not transforming growth factor-[ß] are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9.
25. Wilson NJ, Boniface K, Chan JR. et al. Development, cytokine profile and function of human interleukin 17-producing helperTcells. Nat Immunol 2007;8: 950-7.
26. Chen M-L, Pittet MJ, Gorelik L, et al. RegulatoryT cells suppress tumor-specific CD8 Tcell cytotoxicity throughTGF-{ß} signals in vivo. Proc Natl Acad Sci USA 2005;102:419-24.
27. Kryczek I, Wei S, Zou L, et al. Cutting edge:Th17 and regulatoryTcell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730-3.
28. SasadaT, Kimura M.YoshidaY, Kanai M.Takabayashi A. CD4+CD25+ regulatoryTcells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-99.
29. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461 -5.
30. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-41.
31. Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007;445:931-5.
32. Zheng Y, Rudensky AY Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007;8:457-62.
33. Sato W, Aranami T, Yamamura T. Cutting edge: human Th17 cells are identified as bearing CCR2+CCR5- phenotype. J Immunol 2007,178:7525-9.
34. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006;2:e25.
35. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
36. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 2007;28:207-12.
37. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
38. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006;25: 195-201.
39. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.